Medical Expenditures Attributed to Asthma and Chronic Obstructive Pulmonary Disease Among Workers — United States, 2011–2015

Syamlal, Girija; Bhattacharya, Anasua; Dodd, Katelynn E.

doi:10.15585/mmwr.mm6926a1

Cited by 29 publications

(25 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study contributes to the existing literature by providing a comprehensive overview of respiratory disease spending in the United States, with detailed spending trends over a 21-year period. For common conditions such as COPD and asthma, in which there are existing economic estimates in the literature, our estimates are not directly comparable to other published work because of differences in measurement (spending vs. costs), methodology (e.g., comorbidity adjustment), and the breadth of data sources used in our study ( 8 , 9 , 24 , 25 ). Despite these differences, estimates in our study are similar in magnitude to other published estimates.…”

Section: Discussionmentioning

confidence: 77%

Health Care Spending on Respiratory Diseases in the United States, 1996–2016

Duan

Birger²,

et al. 2023

Am J Respir Crit Care Med

View full text Add to dashboard Cite

Rationale Respiratory conditions account for a large proportion of health care spending in the United States. A full characterization of spending across multiple conditions and over time has not been performed. Objectives To estimate health care spending in the United States for 11 respiratory conditions from 1996 to 2016, providing detailed trends and an evaluation of factors associated with spending growth. Methods We extracted data from the Institute of Health Metrics and Evaluation’s Disease Expenditure Project Database, producing annual estimates in spending for 38 age and sex groups, 7 types of care, and 3 payer types. We performed a decomposition analysis to estimate the change in spending associated with changes in each of five factors (population growth, population aging, disease prevalence, service usage, and service price and intensity). Measurements and Main Results Total spending across all respiratory conditions in 2016 was $170.8 billion (95% confidence interval [CI], $164.2–179.2 billion), increasing by $71.7 billion (95% CI, $63.2–80.8 billion) from 1996. The respiratory conditions with the highest spending in 2016 were asthma and chronic obstructive pulmonary disease, contributing $35.5 billion (95% CI, $32.4–38.2 billion) and $34.3 billion (95% CI, $31.5–37.3 billion), respectively. Increasing service price and intensity were associated with 81.4% (95% CI, 70.3–93.0%) growth from 1996 to 2016. Conclusions U.S. spending on respiratory conditions is high, particularly for chronic conditions like asthma and chronic obstructive pulmonary disease. Our findings suggest that service price and intensity, particularly for pharmaceuticals, should be a key focus of attention for policymakers seeking to reduce health care spending growth.

show abstract

Section: Discussionmentioning

confidence: 77%

Health Care Spending on Respiratory Diseases in the United States, 1996–2016

Duan

Birger²,

et al. 2023

Am J Respir Crit Care Med

View full text Add to dashboard Cite

show abstract

“…The disorder kills 3 million people every year, making it the third leading cause of death worldwide. The CDC has estimated the total expenditure from 2011 to 2015 on treatment of Asthma and COPD was about $7 billion and $5 billion dollars, respectively [ 3 ]. Thus, pulmonary disorder is a major therapeutics area with intense research going on in the field.…”

Section: Introductionmentioning

confidence: 99%

Physiologically-based pharmacokinetic model for pulmonary disposition of protein therapeutics in humans

Jagdale

Sepp

Shah

2022

J Pharmacokinet Pharmacodyn

View full text Add to dashboard Cite

Lung related disorders like COPD and Asthma, as well as various infectious diseases, form a major therapeutic area which would benefit from a predictive and adaptable mathematical model for describing pulmonary disposition of biological modalities. In this study we fill that gap by extending the cross-species two-pore physiologically-based pharmacokinetic (PBPK) platform with more detailed respiratory tract that includes the airways and alveolar space with epithelial lining fluid. We parameterize the paracellular and FcRn-facilitated exchange pathways between the epithelial lining fluid and lung interstitial space by building a mechanistic model for the exchange between the two. The optimized two-pore PBPK model described pulmonary exposure of several systemically dosed mAbs for which data is available and is also in agreement with the observed levels of endogenous IgG and albumin. The proposed framework can be used to assess pharmacokinetics of new lung-targeting biologic therapies and guide their dosing to achieve desired exposure at the pulmonary site-of-action.

show abstract

“…Respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD) are associated with high costs and economic burdens among the US population. This cost was estimated with annualized total medical expenditures being USD 7 billion for asthma and USD 5 billion for COPD in 2017 [ 1 , 2 , 3 , 4 ]. COPD, which includes emphysema and chronic bronchitis, is the fourth leading cause of death in the US [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Co-Occurring Depression and Associated Healthcare Utilization and Expenditure in Individuals with Respiratory Condition: A Population-Based Study

Sakharkar

Mai

2021

Pharmacy

View full text Add to dashboard Cite

The existing literature is limited on the prevalence of depression among people with respiratory conditions and person-level factors that are associated with increased healthcare utilization and expenditures. The aim of this study was to explore the prevalence, pattern of healthcare use, and expenditures in noninstitutionalized individuals having co-occurring depression with respiratory conditions. The Medical Expenditure Panel Survey (MEPS) data from 2011 to 2017 was used in this study. Our sample included individuals having respiratory conditions (asthma, emphysema, and chronic bronchitis) with and without depression. Healthcare use and expenditure data were analyzed using a chi-square test, t-tests, and multiple linear regression analyses. There were 8848 individuals in the study. The prevalence of comorbid depression was 20%. Individuals with co-occurring depression with respiratory conditions differed significantly from individuals without co-occurring depression for age ≥ 45 years, white, and with ≤2 chronic disease conditions. Depressed individuals with respiratory conditions had higher healthcare utilization and expenditures. The presence of co-occurring depression with respiratory conditions increases the treatment complexity, healthcare utilization, and expenditure. Better treatment and management of these patients may reduce healthcare use and expenditures in the future.

show abstract

Medical Expenditures Attributed to Asthma and Chronic Obstructive Pulmonary Disease Among Workers — United States, 2011–2015

Cited by 29 publications

References 9 publications

Health Care Spending on Respiratory Diseases in the United States, 1996–2016

Health Care Spending on Respiratory Diseases in the United States, 1996–2016

Physiologically-based pharmacokinetic model for pulmonary disposition of protein therapeutics in humans

Co-Occurring Depression and Associated Healthcare Utilization and Expenditure in Individuals with Respiratory Condition: A Population-Based Study

Contact Info

Product

Resources

About